PDSB — PDS Biotechnology Corporation

Summary of PDS Biotechnology Corporation Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: Reported a net loss of $9 million ($0.19 per share) for Q3 2025, an improvement from a net loss of $10.7 million ($0.29 per share) in Q3 2024.
• Operating Expenses: Total operating expenses decreased to $8.1 million from $10.2 million year-over-year, primarily due to lower research and development costs ($4.6 million vs. $6.8 million).
• Cash Position: Cash balance as of September 30, 2025, was $26.2 million, down from $41.7 million at the beginning of the year. The company completed a stock sale generating approximately $5.3 million in gross proceeds.

2. Strategic Updates and Business Highlights

• Clinical Trials: PDS0101 is advancing in the VERSATILE-003 trial for HPV16 positive recurrent and/or metastatic head and neck cancer. The VERSATILE-002 trial has shown promising results, with a median overall survival of 39.3 months and progression-free survival of 10.3 months in patients with a CPS of ≥1.
• FDA Engagement: The company plans to amend the VERSATILE-003 trial protocol to include progression-free survival (PFS) as a primary endpoint, alongside median overall survival (MOS), to potentially expedite regulatory submission.
• Research Collaborations: Ongoing collaborations with the National Cancer Institute and other institutions are supporting the development of PDS0101 and its ADC variant.

3. Forward Guidance and Outlook

• The company is optimistic about the potential of PDS0101, especially given the increasing incidence of HPV-positive head and neck cancers. The strategic amendment to the trial protocol aims to shorten the timeline for regulatory approval and treatment availability for patients.
• Continued patient enrollment in VERSATILE-003 will proceed during the trial's temporary pause, with a focus on maintaining treatment for current participants.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The significant decrease in cash reserves raises concerns about funding future operations and clinical trials, especially given the ongoing losses.
• Trial Duration: The reliance on MOS as a primary endpoint could extend the trial duration, prompting the need for protocol amendments to mitigate this risk.
• Competitive Landscape: There is increasing interest in the head and neck cancer space, particularly regarding bispecific antibodies and ADCs, which could heighten competitive pressures.

5. Notable Q&A Insights

• Patient Management in VERSATILE-003: The company confirmed that patients already enrolled will continue to receive treatment during the protocol amendment discussions with the FDA.
• PFS Expectations: The control arm's PFS is conservatively estimated to be around 3 months, based on historical data from similar studies, which could influence the trial's design and outcomes.
• Training for Investigators: The company emphasized the importance of training investigators to handle potential pseudo-progression in immunotherapy, which is critical for accurate assessment of treatment responses in the expanded trial.

Overall, PDS Biotechnology Corporation is making significant strides in its clinical programs while navigating financial challenges and a competitive landscape. The upcoming discussions with the FDA regarding trial amendments are pivotal for the company's future trajectory.